GB
Ginkgo Bioworks Holdings, Inc.
StreetZero Signal 52
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019.
LATEST FUNDINGRule 144
$23K
Announced 2026-10-19
TOTAL RAISED$800M
IN THE NEWS
- 🔗 Ginkgo Bioworks - Wikipedia
- 🔗 Ginkgo Bioworks IPO Timeline and Financing Details - Forge
- 🔗 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a favorite amongst institutional investors who own 56%
- 🔗 With 48% ownership, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has piqued the interest of institutional investors
- 🔗 Ginkgo begins trading on the NYSE after completing SPAC merger
EMPLOYEES—
FOUNDED2008
HQBOSTON, MA
Industry
Public Equity (NYSE)
Tags
BiotechSynthetic BiologyPublic
Key highlights
- Completed SPAC merger and NYSE listing in September 2021.
- Raised $775 million PIPE with participation from Baillie Gifford, Ark Invest and Cascade Investment.
- Previously valued at $4.2 billion as a private company in 2019.
- Reported $170 million full-year 2025 revenue while focusing on commercializing its synthetic biology platform.
Ask StreetZero about Ginkgo Bioworks Holdings, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NYSE) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account